Luke Evnin, a director at Werewolf Therapeutics, Inc. (NASDAQ: HOWL), sold 30,616 shares of the company’s stock on January 14, 2024. The shares were disposed of at an average price of $0.57, resulting in a total transaction value of $17,451.12. Following this sale, Evnin retains ownership of 2,236,055 shares, which are currently valued at approximately $1,274,551.35.
This transaction marks a 1.35% decrease in Evnin’s overall stake in the biotechnology firm. The details were disclosed in a legal filing with the U.S. Securities and Exchange Commission (SEC), which is publicly accessible.
Current Stock Performance and Financial Metrics
As of the latest trading session, shares of Werewolf Therapeutics opened at $0.55. The company exhibits a strong liquidity position, with a quick ratio and current ratio both standing at 3.87. The debt-to-equity ratio is reported at 0.73. Over the past fifty days, the stock’s moving average was $0.84, while the two-hundred-day moving average stood at $1.23.
Werewolf Therapeutics has experienced volatility in its stock price, with a 52-week low of $0.53 and a 52-week high of $2.38. The company currently has a market capitalization of $26.74 million, a PE ratio of -0.34, and a beta of 0.77.
Institutional Investor Activity
Several institutional investors have recently adjusted their holdings in Werewolf Therapeutics. Notably, Quadrature Capital Ltd acquired a new position valued at approximately $28,000 during the second quarter. Similarly, Qube Research & Technologies Ltd invested around $48,000 during the same period, while AQR Capital Management LLC added a stake worth about $79,000 in the first quarter.
Additionally, Y Intercept Hong Kong Ltd purchased shares valued at approximately $92,000, and Bridgeway Capital Management LLC increased its holdings by 157.7%, now owning 102,000 shares after acquiring an additional 62,414 shares. Institutional investors and hedge funds collectively hold 64.84% of the stock.
Analyst Ratings and Market Outlook
Recent analyst evaluations have shown a mixed outlook for Werewolf Therapeutics. On December 19, 2023, Citigroup downgraded the company from a “market outperform” to a “market perform” rating. Meanwhile, Bank of America revised its target price from $8.00 to $7.00 while retaining a “buy” rating. In contrast, HC Wainwright lowered its price objective from $10.00 to $4.00, maintaining a “buy” rating in its recent analysis.
Weiss Ratings issued a “sell (d-)” rating on October 8, 2023, while Wedbush downgraded the company from “outperform” to “neutral” with a $1.00 target price. Overall, three analysts have rated the stock as a Buy, four have given it a Hold rating, and one has issued a Sell rating. MarketBeat reports a consensus rating of “Hold” and an average target price of $3.75.
Company Overview
Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company that focuses on developing next-generation immunotherapies for treating solid tumors. The company employs its proprietary Conditional Activation Platform, designed to keep therapeutic molecules inactive in healthy tissues while selectively activating them in the tumor microenvironment. This approach aims to enhance anti-tumor efficacy while minimizing systemic toxicity.
Using this innovative platform, Werewolf Therapeutics is advancing multiple programs, including conditionally activated cytokine candidates and bi-specific antibody constructs, reflecting its commitment to transforming cancer treatment.
